NCT00489983已完成2 期
A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 91
- 试验地点
- 3
- 主要终点
- To evaluate efficacy.
研究概览
简要总结
This study is for elderly patients who haven't been given prior chemotherapy or for patients who cannot be treated with platinum based chemotherapy. The patients who are eligible for this study will have been diagnosed with advanced or metastatic non-small cell lung cancer. The patients will be randomly assigned to one of two treatment options: single agent pemetrexed or single agent pemetrexed with single agent gemcitabine following right after the pemetrexed treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically or cytologically confirmed NSCLC not amenable to surgery or radiotherapy of curative intent
- •locally advanced or metastatic Stage IIIb (with N3 supraclavicular or T4 for pleural effusion) or IV NSCLC
- •no prior chemotherapy
- •measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Therasse et al. 2000)
- •men and women greater than or equal to 70 years of age or patients who, in the investigator's opinion, are not eligible for platinum-based chemotherapy
排除标准
- •have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
- •have symptomatic brain metastases
- •have a history or presence of other malignancy except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years before without recurrence (excluding melanoma, breast cancer and hypernephroma)
- •are unable to interrupt therapy with aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) such as naproxen, piroxicam, diflunisal, or nabumetone around each dose of pemetrexed (5 days for short-acting or 8 days for long acting preparations)
- •are unable or unwilling to take steroids
- •are unable or unwilling to take folic acid or vitamin B12 supplementation
- •have clinically detectable (by physical examination) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
- •have other serious concomitant illness or medical conditions according to investigator criteria, including but not limited to the following:
- •congestive heart failure or angina pectoris, except if it is medically controlled
- •previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or arrhythmias
- •active infection requiring iv antibiotics
- •active ulcer, unstable diabetes mellitus, or other contra-indication to corticotherapy
- •superior vena cava syndrome
结局指标
主要结局
To evaluate efficacy.
次要结局
- To evaluate toxicity.
- To evaluate response.
- To evaluate overall survival, duration of overall response, and duration of stable disease.
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT01403246Gruppo Italiano Malattie EMatologiche dell'Adulto9
已完成
2 期
Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and BlinatumomabB-Precursor ALLNCT03480438Goethe University52
终止
2 期
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung CancerCarcinoma, Non-small Cell LungNCT02590003Yale University3
进行中（未招募）
2 期
Ibrutinib + R-CHOP Followed by Ibrutinib MaintenanceDLBCLNCT03731234Fondazione Italiana Linfomi - ETS75
撤回
不适用
Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast CancerER-positive Her2-negative Early Breast CancerNCT03080428UNICANCER